Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Nvidia Options Price in $280 Billion Earnings Swing 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
California Seeks Paramount Divestitures in Warner Bros. Merger 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
BASKING RIDGE, N.J., May 03, 2018 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Thursday, May 10, 2018.
Caladrius’ management will host a conference call for the investment community beginning at 4:30 p.m. ET on Thursday, May 10, 2018 to discuss the financial results, provide a company update and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing (866) 595-8403 (domestic), or (706) 758-9979 (international), and providing conference ID: 9763239. The call will also be broadcast live on the Internet via the Company’s website at www.caladrius.com/investors/news-events.
For those unable to participate in the live conference call or webcast, a replay will be available beginning May 10, 2018 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 9763239.
The webcast will be archived on the Company’s website for 90 days.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, a CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia being conducted in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations. For more information about Caladrius please visit www.caladrius.com.
Contacts:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: [email protected]
LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]
